Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis

The rate of diagnosis of colonization/infection of the airways with Achromobacter xylosoxidans has increased in cystic fibrosis patients, but its clinical significance is still controversial. This retrospective, case-control study aimed to evaluate the clinical impact of A. xylosoxidans colonization/infection in cystic fibrosis patients. Individuals who were chronically colonized/infected (n=10), intermittently colonized/infected (n=15), and never colonized/infected with A. xylosoxidans (n=18) were retrospectively evaluated during two periods that were 2 years apart. Demographic characteristics, clinical data, lung function, and chronic bacterial co-colonization data were evaluated. Of the total study population, 87% were pediatric patients and 65.1% were female. Individuals chronically colonized/infected with A. xylosoxidans had decreased forced expiratory volume in 1 s (51.7% in the chronic colonization/infection group vs 82.7% in the intermittent colonization/infection group vs 76% in the never colonized/infected group). Compared with the other two groups, the rate of co-colonization with methicillin-resistant Staphylococcus aureus was higher in individuals chronically colonized/infected with A. xylosoxidans (P=0.002). Changes in lung function over 2 years in the three groups were not significant, although a trend toward a greater decrease in lung function was observed in the chronically colonized/infected group. Compared with the other two groups, there was a greater number of annual hospitalizations in patients chronically colonized/infected with A. xylosoxidans (P=0.033). In cystic fibrosis patients, there was an increased frequency of A. xylosoxidans colonization/infection in children, and lung function was reduced in patients who were chronically colonized/infected with A. xylosoxidans. Additionally, there were no differences in clinical outcomes during the 2-year period, except for an increased number of hospitalizations in patients with A. xylosoxidans.

Saved in:
Bibliographic Details
Main Authors: Firmida,M.C., Pereira,R.H.V., Silva,E.A.S.R., Marques,E.A., Lopes,A.J.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2016
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000400703
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2016000400703
record_format ojs
spelling oai:scielo:S0100-879X20160004007032016-03-15Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosisFirmida,M.C.Pereira,R.H.V.Silva,E.A.S.R.Marques,E.A.Lopes,A.J. Cystic fibrosis Achromobacter spp. Achromobacter xylosoxidans Microbiology The rate of diagnosis of colonization/infection of the airways with Achromobacter xylosoxidans has increased in cystic fibrosis patients, but its clinical significance is still controversial. This retrospective, case-control study aimed to evaluate the clinical impact of A. xylosoxidans colonization/infection in cystic fibrosis patients. Individuals who were chronically colonized/infected (n=10), intermittently colonized/infected (n=15), and never colonized/infected with A. xylosoxidans (n=18) were retrospectively evaluated during two periods that were 2 years apart. Demographic characteristics, clinical data, lung function, and chronic bacterial co-colonization data were evaluated. Of the total study population, 87% were pediatric patients and 65.1% were female. Individuals chronically colonized/infected with A. xylosoxidans had decreased forced expiratory volume in 1 s (51.7% in the chronic colonization/infection group vs 82.7% in the intermittent colonization/infection group vs 76% in the never colonized/infected group). Compared with the other two groups, the rate of co-colonization with methicillin-resistant Staphylococcus aureus was higher in individuals chronically colonized/infected with A. xylosoxidans (P=0.002). Changes in lung function over 2 years in the three groups were not significant, although a trend toward a greater decrease in lung function was observed in the chronically colonized/infected group. Compared with the other two groups, there was a greater number of annual hospitalizations in patients chronically colonized/infected with A. xylosoxidans (P=0.033). In cystic fibrosis patients, there was an increased frequency of A. xylosoxidans colonization/infection in children, and lung function was reduced in patients who were chronically colonized/infected with A. xylosoxidans. Additionally, there were no differences in clinical outcomes during the 2-year period, except for an increased number of hospitalizations in patients with A. xylosoxidans.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.49 n.4 20162016-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000400703en10.1590/1414-431X20155097
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Firmida,M.C.
Pereira,R.H.V.
Silva,E.A.S.R.
Marques,E.A.
Lopes,A.J.
spellingShingle Firmida,M.C.
Pereira,R.H.V.
Silva,E.A.S.R.
Marques,E.A.
Lopes,A.J.
Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis
author_facet Firmida,M.C.
Pereira,R.H.V.
Silva,E.A.S.R.
Marques,E.A.
Lopes,A.J.
author_sort Firmida,M.C.
title Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis
title_short Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis
title_full Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis
title_fullStr Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis
title_full_unstemmed Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis
title_sort clinical impact of achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis
description The rate of diagnosis of colonization/infection of the airways with Achromobacter xylosoxidans has increased in cystic fibrosis patients, but its clinical significance is still controversial. This retrospective, case-control study aimed to evaluate the clinical impact of A. xylosoxidans colonization/infection in cystic fibrosis patients. Individuals who were chronically colonized/infected (n=10), intermittently colonized/infected (n=15), and never colonized/infected with A. xylosoxidans (n=18) were retrospectively evaluated during two periods that were 2 years apart. Demographic characteristics, clinical data, lung function, and chronic bacterial co-colonization data were evaluated. Of the total study population, 87% were pediatric patients and 65.1% were female. Individuals chronically colonized/infected with A. xylosoxidans had decreased forced expiratory volume in 1 s (51.7% in the chronic colonization/infection group vs 82.7% in the intermittent colonization/infection group vs 76% in the never colonized/infected group). Compared with the other two groups, the rate of co-colonization with methicillin-resistant Staphylococcus aureus was higher in individuals chronically colonized/infected with A. xylosoxidans (P=0.002). Changes in lung function over 2 years in the three groups were not significant, although a trend toward a greater decrease in lung function was observed in the chronically colonized/infected group. Compared with the other two groups, there was a greater number of annual hospitalizations in patients chronically colonized/infected with A. xylosoxidans (P=0.033). In cystic fibrosis patients, there was an increased frequency of A. xylosoxidans colonization/infection in children, and lung function was reduced in patients who were chronically colonized/infected with A. xylosoxidans. Additionally, there were no differences in clinical outcomes during the 2-year period, except for an increased number of hospitalizations in patients with A. xylosoxidans.
publisher Associação Brasileira de Divulgação Científica
publishDate 2016
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000400703
work_keys_str_mv AT firmidamc clinicalimpactofachromobacterxylosoxidanscolonizationinfectioninpatientswithcysticfibrosis
AT pereirarhv clinicalimpactofachromobacterxylosoxidanscolonizationinfectioninpatientswithcysticfibrosis
AT silvaeasr clinicalimpactofachromobacterxylosoxidanscolonizationinfectioninpatientswithcysticfibrosis
AT marquesea clinicalimpactofachromobacterxylosoxidanscolonizationinfectioninpatientswithcysticfibrosis
AT lopesaj clinicalimpactofachromobacterxylosoxidanscolonizationinfectioninpatientswithcysticfibrosis
_version_ 1756391515426390016